Allspring Global Investments Holdings LLC Raises Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Allspring Global Investments Holdings LLC grew its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 1.9% during the first quarter, Holdings Channel reports. The institutional investor owned 184,934 shares of the biotechnology company’s stock after buying an additional 3,537 shares during the period. Allspring Global Investments Holdings LLC’s holdings in United Therapeutics were worth $42,483,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Diversified Trust Co raised its stake in United Therapeutics by 286.6% during the 1st quarter. Diversified Trust Co now owns 5,045 shares of the biotechnology company’s stock worth $1,159,000 after acquiring an additional 3,740 shares during the period. Compass Ion Advisors LLC increased its stake in shares of United Therapeutics by 3.6% in the first quarter. Compass Ion Advisors LLC now owns 2,892 shares of the biotechnology company’s stock worth $664,000 after purchasing an additional 101 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its position in shares of United Therapeutics by 14.4% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 3,291 shares of the biotechnology company’s stock valued at $756,000 after purchasing an additional 413 shares during the period. New England Research & Management Inc. lifted its stake in shares of United Therapeutics by 29.8% during the 1st quarter. New England Research & Management Inc. now owns 10,430 shares of the biotechnology company’s stock valued at $2,396,000 after buying an additional 2,395 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in United Therapeutics by 85.4% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 2,585 shares of the biotechnology company’s stock worth $594,000 after buying an additional 1,191 shares during the period. 94.08% of the stock is currently owned by institutional investors.

Insider Activity

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Monday, July 1st. The shares were sold at an average price of $320.45, for a total transaction of $1,153,620.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $41,658.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Nilda Mesa sold 266 shares of the stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total value of $84,742.28. Following the sale, the director now directly owns 5,107 shares in the company, valued at $1,626,988.06. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $320.45, for a total value of $1,153,620.00. Following the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $41,658.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 108,944 shares of company stock valued at $28,686,812. 12.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on UTHR. Wells Fargo & Company boosted their price objective on United Therapeutics from $325.00 to $350.00 and gave the company an “overweight” rating in a research report on Wednesday, June 12th. Oppenheimer upped their price target on United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research note on Thursday, May 2nd. HC Wainwright reiterated a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a research report on Thursday, May 2nd. JPMorgan Chase & Co. upped their target price on shares of United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 21st. Finally, The Goldman Sachs Group raised their target price on shares of United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. One analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $312.22.

United Therapeutics Stock Performance

United Therapeutics stock opened at $311.04 on Thursday. The company’s 50-day moving average price is $279.61 and its 200-day moving average price is $245.36. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. The company has a market cap of $13.80 billion, a PE ratio of 14.71, a price-to-earnings-growth ratio of 1.39 and a beta of 0.55. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $325.00.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, topping the consensus estimate of $5.63 by $0.54. The company had revenue of $677.70 million for the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The firm’s revenue for the quarter was up 33.7% on a year-over-year basis. During the same period in the previous year, the firm posted $4.86 earnings per share. On average, equities research analysts forecast that United Therapeutics Co. will post 24.73 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.